ArticleCureus2024
Detection of SARS-CoV-2 Variants Imported Through Land Borders at the Height of the COVID-19 Pandemic in Ghana, 2022.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The World Health Organization recommends surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at points of entry to systematically collect and analyze data to inform decisions about the effective and appropriate use of resources needed for interventions. This study sought to determine the prevalence of SARS-CoV-2 and its variants imported into Ghana by travelers entering the country via land borders from February to July 2022. Methods A cross-sectional approach was employed, where recruited participants consented to the collection of oropharyngeal and nasopharyngeal samples. Specimens were analyzed for the presence of SARS-CoV-2 ribonucleic acid (RNA) using a commercially available VeriQ nCoV-OM COVID-19 Multiplex Detection kit. Amplicon sequencing protocols (ARTIC network, Oxford Nanopore Technologies (ONT), New England Biolabs, British Columbia Centre for Disease Control (BCCDC), COVID-19 Genomics UK (COG-UK), Canadian COVID-19 Genomics Network (CanCOGen), and ONT MinION) were used for SARS-CoV-2 sequencing. Logistic regression and phylogenetic analyses were conducted on the generated data. Results We detected a SARS-CoV-2 prevalence of 3.6% (170/4,621) among a total of 4,621 travelers screened. The average age of travelers was 32.11 ± 11.77, with the majority being male (68%, 3,132/4,621). After adjusting for educational status, household size, vaccination status, and study site, those with primary and tertiary education levels had 1.74 (95% CI: 1.16-2.62, P = 0.007) and 2.27 (95% CI: 1.27-4.05, P = 0.006) higher odds of testing positive for SARS-CoV-2 compared to those with no education. Vaccinated travelers had 0.65 odds (95% CI: 0.48-0.89, P = 0.007) of testing positive for SARS-CoV-2. The Omicron variant (B.1.1.529) emerged as the predominant lineage, constituting 77% (27/35) of isolates, compared to Alpha, Delta, and Recombinant variants. Phylogenetic analysis corroborated this finding, highlighting Delta and Omicron as the dominant circulating SARS-CoV-2 variants. Notably, Ghanaian strains from this study clustered with global variants, suggesting multiple introductions, likely through land borders. Conclusion A low prevalence of SARS-CoV-2 was recorded in this study, prompting the decision to reopen land borders and ease pandemic-related travel restrictions. Omicron was identified as the dominant variant. These findings emphasize the crucial role of routine surveillance at port health and advocate for a collaborative approach to addressing public health crises, preventing unnecessary travel and trade restrictions through data-based decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.